According to the immunophenotypic classification, BC is categorized into hormone receptor-positive (including estrogen receptor and progesterone receptors), HER2 overexpressed BC, and triple-negative breast cancer (TNBC) (Hammond et al., 2010; Garrido-Castro et al., 2019). Here, ERBB2 is linked to breast cancer.